Dr. Judy H. Chiao Net Worth

The estimated Net Worth of Judy Chiao is at least $558 millier dollars as of 9 June 2008. Dr Chiao owns over 2,000 units of Cyclacel Pharmaceuticals Inc stock worth over $52,503 and over the last 19 years he sold CYCC stock worth over $0. In addition, he makes $505,064 as VP of Clinical Devel. & Regulatory Affairs at Cyclacel Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dr Chiao CYCC stock SEC Form 4 insiders trading

Dr has made over 1 trades of the Cyclacel Pharmaceuticals Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of CYCC stock worth $4,280 on 9 June 2008.

The largest trade he's ever made was buying 2,000 units of Cyclacel Pharmaceuticals Inc stock on 9 June 2008 worth over $4,280. On average, Dr trades about 111 units every 0 days since 2006. As of 9 June 2008 he still owns at least 48,168 units of Cyclacel Pharmaceuticals Inc stock.

You can see the complete history of Dr Chiao stock trades at the bottom of the page.

Dr. Judy H. Chiao biography

Dr. Judy H. Chiao is the VP of Clinical Devel. & Regulatory Affairs at Cyclacel Pharmaceuticals Inc.

What is the salary of Dr Chiao?

As the VP of Clinical Devel. & Regulatory Affairs of Cyclacel Pharmaceuticals Inc, the total compensation of Dr Chiao at Cyclacel Pharmaceuticals Inc is $505,064. There are 1 executives at Cyclacel Pharmaceuticals Inc getting paid more, with Spiro George Rombotis having the highest compensation of $772,644.

How old is Dr Chiao?

Dr Chiao is 60, he's been the VP of Clinical Devel. & Regulatory Affairs of Cyclacel Pharmaceuticals Inc since . There are 3 older and no younger executives at Cyclacel Pharmaceuticals Inc. The oldest executive at Cyclacel Pharmaceuticals Inc is Dr. Robert Westwood Ph.D., 77, who is the Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel..

What's Dr Chiao's mailing address?

Judy's mailing address filed with the SEC is 200 CONNELL DRIVE, SUITE 1500, , BERKELEY HEIGHTS, NJ, 07922.

Insiders trading at Cyclacel Pharmaceuticals Inc

Over the last 19 years, insiders at Cyclacel Pharmaceuticals Inc have traded over $6,366,241 worth of Cyclacel Pharmaceuticals Inc stock and bought 3,400,245 units worth $14,147,428 . The most active insiders traders include Capital Ltd Portfolio Servi..., Austin W & Greenhouse David... et Kevin Ctang Capital Managem.... On average, Cyclacel Pharmaceuticals Inc executives and independent directors trade stock every 78 days with the average trade being worth of $115,984. The most recent stock trade was executed by Paul Mc Barron on 21 December 2023, trading 1,886 units of CYCC stock currently worth $6,262.

What does Cyclacel Pharmaceuticals Inc do?

cyclacel limited is a pharmaceuticals company located in 46-48 e smithfield, london, united kingdom.

Complete history of Dr Chiao stock trades at Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc executives and stock owners

Cyclacel Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Spiro George Rombotis,
  Pres, CEO & Exec. Director
• Dr. Judy H. Chiao,
  VP of Clinical Devel. & Regulatory Affairs
• Paul McBarron,
  Exec. VP, CFO, COO, Sec. & Exec. Director
• Dr. Mark H. Kirschbaum M.D.,
  Sr. VP & Chief Medical Officer
• Dr. Robert Westwood Ph.D.,
  Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel.
• Gill Christie,
  Director of HR
• Gregory T. Hradsky,
  Director
• Kevin Ctang Capital Managem...,
  
• Judy Chiao,
  V.P., Clin. Dev. & Reg. Aff.
• Nicholas G Bacopoulos,
  Director
• Christopher S Henney,
  Director
• David C Uprichard,
  Director
• Lloyd Sems,
  Director
• Sam L Barker,
  Director
• John Michael Middlecott Banham,
  Director
• Spiro George Rombotis,
  President and CEO
• Capital Ltd Portfolio Servi...,
  
• Robert J. Spiegel,
  Director
• Brian Schwartz,
  Interim Chief Medical Officer
• Daniel K Spiegelman,
  Director
• Austin W & Greenhouse David...,
  10% owner
• Stanley Morgan,
  10% owner
• Robert Edward Sosnowski,
  VP, Marketing & Sales
• James Edeerfield Capital Lp...,
  
• Willian Collins,
  General Manager
• Gregory Reyes,
  Senior VP, Research
• Pierre Legault,
  Director
• John Gordon Mc Vie,
  Director
• Robert Westwood,
  V.P., Chem. & Preclin. Dev.
• Jean Deleage,
  
• Robert Jackson,
  S.V.P. & Chief Scientific Offi
• Mark Kirschbaum,
  Chief Medical Officer
• Paul Mc Barron,
  See Remarks
• Karin L Walker,
  Director
• Kenneth M. Ferguson,
  Director